View Past PerformanceThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsOtonomy 대차대조표 건전성재무 건전성 기준 점검 3/6Otonomy 의 총 주주 지분은 $21.4M 이고 총 부채는 $16.1M, 이는 부채 대 자기자본 비율을 75.4% 로 가져옵니다. 총자산과 총부채는 각각 $57.5M 및 $36.1M 입니다.핵심 정보75.38%부채/자본 비율US$16.13m부채이자보상배율n/a현금US$40.15m자본US$21.40m총부채US$36.13m총자산US$57.53m최근 재무 건전성 업데이트분석 기사 • Feb 02Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...모든 업데이트 보기Recent updates공시 • Feb 18Otonomy, Inc. Announces Executive ChangesOn February 15, 2023, the board of directors of the Otonomy, Inc. appointed H. Michael Hogan, a representative of Armanino LLP (Armanino), a consultant to the Company, to the Board. In connection and simultaneously with Mr. Hogan’s appointment to the Board, the size of the Board was reduced to one and Jay Lichter, Ph.D., James B. Breitmeyer, M.D., Ph.D., Jill Broadfoot, Vickie Capps, Ciara Kennedy, Ph.D., Iain McGill, Theodore R. Schroeder and David A. Weber, Ph.D. resigned from the Board. The directors did not resign because of any disagreement with the Company relating to its operations, policies or practices. Mr. Hogan will serve as a director pursuant to the Company’s engagement of Armanino, but will not receive any compensation for his service as the Company’s sole director.Price Target Changed • Nov 16Price target increased to US$9.00Up from US$6.00, the current price target is provided by 1 analyst. New target price is 6,823% above last closing price of US$0.13. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Price Target Changed • Aug 02Price target decreased to US$5.83Down from US$6.63, the current price target is an average from 4 analysts. New target price is 2,240% above last closing price of US$0.25. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$0.72 next year compared to a net loss per share of US$0.81 last year.Seeking Alpha • Aug 01Otonomy crashes 73% as mid-stage trial for tinnitus candidate failsThe shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.Seeking Alpha • Jul 25Otonomy GAAP EPS of -$0.19 beats by $0.01Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.Reported Earnings • May 10First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.23 loss in 1Q 2021)First quarter 2022 results: US$0.20 loss per share. Net loss: US$13.6m (loss widened 11% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 6.9% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 191% above last closing price of US$2.23. Stock is down 9.7% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Price Target Changed • Apr 21Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 190% above last closing price of US$2.24. Stock is down 2.6% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Seeking Alpha • Apr 04Otonomy: Hearing Loss And Tinnitus Data In 2022Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indications is an extremely difficult task.Reported Earnings • Mar 03Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.81 loss per share (up from US$1.10 loss in FY 2020). Net loss: US$51.2m (loss widened 14% from FY 2020). Products in clinical trials Phase II: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.5%. Over the next year, revenue is expected to shrink by 100% compared to a 20% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.22 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$12.9m (loss widened 19% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Major Estimate Revision • Aug 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$183.8k to US$158.3k. EPS estimate increased from -US$0.81 to -US$0.78 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.30 unchanged from last update. Share price fell 5.5% to US$1.56 over the past week.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.37 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$12.5m (loss widened 9.2% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.분석 기사 • Jun 16Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time BeingShareholders of Otonomy, Inc. ( NASDAQ:OTIC ) will have been dismayed by the negative share price return over the last...Major Estimate Revision • May 18Consensus revenue estimates increase to US$183.8kThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$118.8k to US$183.8k. Forecast losses expected to reduce from -US$0.87 to -US$0.81 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.30 unchanged from last update. Share price rose 15% to US$2.37 over the past week.Reported Earnings • May 13First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.38 loss in 1Q 2020)First quarter 2021 results: Net loss: US$12.2m (loss widened 3.8% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Major Estimate Revision • Apr 14Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -US$1.09 to -US$0.87 per share. Revenue forecast unchanged from US$118.8k at last update. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target up from US$5.91 to US$6.10. Share price fell 16% to US$2.17 over the past week.Is New 90 Day High Low • Feb 23New 90-day low: US$3.00The company is down 31% from its price of US$4.37 on 24 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$101 per share.Major Estimate Revision • Feb 18Analysts lower revenue estimates to US$91.7kThe 2021 consensus revenue estimate decreased from US$7.56m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.01 to -US$1.06 for the same period. The Pharmaceuticals industry in the US is expected to see an average net income growth of 14% next year. The consensus price target of US$10.80 was unchanged from the last update. Share price is up 5.2% to US$5.63 over the past week.Analyst Estimate Surprise Post Earnings • Feb 13Revenue and earnings miss expectationsRevenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 5.6%. Over the next year, revenue is forecast to grow 2,669%, compared to a 31% growth forecast for the Pharmaceuticals industry in the US.Reported Earnings • Feb 13Full year 2020 earnings released: US$1.10 loss per share (vs US$1.45 loss in FY 2019)Full year 2020 results: Net loss: US$44.7m (flat on FY 2019). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.분석 기사 • Feb 02Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Price Target Changed • Dec 19Price target raised to US$10.80Up from US$9.40, the current price target is an average from 5 analysts. The new target price is 69% above the current share price of US$6.38. As of last close, the stock is up 158% over the past year.Is New 90 Day High Low • Dec 18New 90-day high: US$5.98The company is up 51% from its price of US$3.95 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$149 per share.분석 기사 • Dec 11Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?A look at the shareholders of Otonomy, Inc. ( NASDAQ:OTIC ) can tell us which group is most powerful. Institutions will...Is New 90 Day High Low • Dec 02New 90-day high: US$4.79The company is up 29% from its price of US$3.70 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$125 per share.Analyst Estimate Surprise Post Earnings • Nov 07Revenue and earnings miss expectationsRevenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 1,756%, compared to a 30% growth forecast for the Pharmaceuticals industry in the US.Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.22 loss per shareThird quarter 2020 results: Net loss: US$10.9m (loss widened 8.2% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 03New 90-day high: US$4.44The company is up 41% from its price of US$3.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$117 per share.재무 상태 분석단기부채: OTIC 의 단기 자산 ( $43.9M )이 단기 부채( $25.3M ).장기 부채: OTIC의 단기 자산($43.9M)이 장기 부채($10.9M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: OTIC 총 부채보다 더 많은 현금을 보유하고 있습니다.부채 감소: OTIC의 부채 대비 자본 비율은 지난 5년 동안 0%에서 75.4%로 증가했습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: OTIC 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.예측 현금 활주로: 무료 현금 흐름이 매년 16.3 %의 역사적 비율로 계속 증가할 경우 OTIC 의 현금 활주로는 1년 미만입니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/04/13 20:03종가2023/04/11 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Otonomy, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Aaron GalBernsteinSumant Satchidanand KulkarniBofA Global ResearchCharles DuncanCantor Fitzgerald & Co.6명의 분석가 더 보기
분석 기사 • Feb 02Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
공시 • Feb 18Otonomy, Inc. Announces Executive ChangesOn February 15, 2023, the board of directors of the Otonomy, Inc. appointed H. Michael Hogan, a representative of Armanino LLP (Armanino), a consultant to the Company, to the Board. In connection and simultaneously with Mr. Hogan’s appointment to the Board, the size of the Board was reduced to one and Jay Lichter, Ph.D., James B. Breitmeyer, M.D., Ph.D., Jill Broadfoot, Vickie Capps, Ciara Kennedy, Ph.D., Iain McGill, Theodore R. Schroeder and David A. Weber, Ph.D. resigned from the Board. The directors did not resign because of any disagreement with the Company relating to its operations, policies or practices. Mr. Hogan will serve as a director pursuant to the Company’s engagement of Armanino, but will not receive any compensation for his service as the Company’s sole director.
Price Target Changed • Nov 16Price target increased to US$9.00Up from US$6.00, the current price target is provided by 1 analyst. New target price is 6,823% above last closing price of US$0.13. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Price Target Changed • Aug 02Price target decreased to US$5.83Down from US$6.63, the current price target is an average from 4 analysts. New target price is 2,240% above last closing price of US$0.25. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$0.72 next year compared to a net loss per share of US$0.81 last year.
Seeking Alpha • Aug 01Otonomy crashes 73% as mid-stage trial for tinnitus candidate failsThe shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.
Seeking Alpha • Jul 25Otonomy GAAP EPS of -$0.19 beats by $0.01Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.
Reported Earnings • May 10First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.23 loss in 1Q 2021)First quarter 2022 results: US$0.20 loss per share. Net loss: US$13.6m (loss widened 11% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 6.9% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 191% above last closing price of US$2.23. Stock is down 9.7% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Price Target Changed • Apr 21Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 190% above last closing price of US$2.24. Stock is down 2.6% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Seeking Alpha • Apr 04Otonomy: Hearing Loss And Tinnitus Data In 2022Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indications is an extremely difficult task.
Reported Earnings • Mar 03Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.81 loss per share (up from US$1.10 loss in FY 2020). Net loss: US$51.2m (loss widened 14% from FY 2020). Products in clinical trials Phase II: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.5%. Over the next year, revenue is expected to shrink by 100% compared to a 20% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.22 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$12.9m (loss widened 19% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Aug 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$183.8k to US$158.3k. EPS estimate increased from -US$0.81 to -US$0.78 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.30 unchanged from last update. Share price fell 5.5% to US$1.56 over the past week.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.37 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$12.5m (loss widened 9.2% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
분석 기사 • Jun 16Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time BeingShareholders of Otonomy, Inc. ( NASDAQ:OTIC ) will have been dismayed by the negative share price return over the last...
Major Estimate Revision • May 18Consensus revenue estimates increase to US$183.8kThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$118.8k to US$183.8k. Forecast losses expected to reduce from -US$0.87 to -US$0.81 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.30 unchanged from last update. Share price rose 15% to US$2.37 over the past week.
Reported Earnings • May 13First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.38 loss in 1Q 2020)First quarter 2021 results: Net loss: US$12.2m (loss widened 3.8% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Apr 14Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -US$1.09 to -US$0.87 per share. Revenue forecast unchanged from US$118.8k at last update. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target up from US$5.91 to US$6.10. Share price fell 16% to US$2.17 over the past week.
Is New 90 Day High Low • Feb 23New 90-day low: US$3.00The company is down 31% from its price of US$4.37 on 24 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$101 per share.
Major Estimate Revision • Feb 18Analysts lower revenue estimates to US$91.7kThe 2021 consensus revenue estimate decreased from US$7.56m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.01 to -US$1.06 for the same period. The Pharmaceuticals industry in the US is expected to see an average net income growth of 14% next year. The consensus price target of US$10.80 was unchanged from the last update. Share price is up 5.2% to US$5.63 over the past week.
Analyst Estimate Surprise Post Earnings • Feb 13Revenue and earnings miss expectationsRevenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 5.6%. Over the next year, revenue is forecast to grow 2,669%, compared to a 31% growth forecast for the Pharmaceuticals industry in the US.
Reported Earnings • Feb 13Full year 2020 earnings released: US$1.10 loss per share (vs US$1.45 loss in FY 2019)Full year 2020 results: Net loss: US$44.7m (flat on FY 2019). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
분석 기사 • Feb 02Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Price Target Changed • Dec 19Price target raised to US$10.80Up from US$9.40, the current price target is an average from 5 analysts. The new target price is 69% above the current share price of US$6.38. As of last close, the stock is up 158% over the past year.
Is New 90 Day High Low • Dec 18New 90-day high: US$5.98The company is up 51% from its price of US$3.95 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$149 per share.
분석 기사 • Dec 11Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?A look at the shareholders of Otonomy, Inc. ( NASDAQ:OTIC ) can tell us which group is most powerful. Institutions will...
Is New 90 Day High Low • Dec 02New 90-day high: US$4.79The company is up 29% from its price of US$3.70 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$125 per share.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue and earnings miss expectationsRevenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 1,756%, compared to a 30% growth forecast for the Pharmaceuticals industry in the US.
Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.22 loss per shareThird quarter 2020 results: Net loss: US$10.9m (loss widened 8.2% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 03New 90-day high: US$4.44The company is up 41% from its price of US$3.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$117 per share.